Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as u⦠read more
Healthcare
Drug ManufacturersāSpecialty & Generic
13 years
USD
Exclusive to Premium users
$1.40
Price+6.85%
$0.09
$227.359m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$308.519m
-
1y CAGR-
3y CAGR-
5y CAGR-$7.885m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.05
-
1y CAGR-
3y CAGR-
5y CAGR-$308.162m
$342.946m
Assets$651.108m
Liabilities$598.669m
Debt174.6%
7.5x
Debt to EBITDA$29.936m
-
1y CAGR-
3y CAGR-
5y CAGR